Sharp Therapeutics Corp. (TSXV:SHRX)
Canada
· Delayed Price · Currency is CAD 1.850
0.00 (0.00%)
At close: Apr 30, 2025
Sharp Therapeutics Company Description
Sharp Therapeutics Corp., a preclinical-stage drug discovery company, developes therapeutics for genetic diseases.
The company engages in the development of the CoreX, a suite of biology technologies, enables discovery of compounds that correct the mutational defect; AlloChem, a compound library, binds proteins allosterically, thus stabilizing and activating them; And Mine, a proprietary IP-protected analytics platform, captures all data for all AlloChem compounds in all CoreX assays.
Sharp Therapeutics Corp. is headquartered in Pittsburgh, Pennsylvania.
Sharp Therapeutics Corp.
| Country | Canada |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Scott Sneddon |
Contact Details
Address: 2403 Sidney Street Pittsburgh, Ontario 15203 United States | |
| Phone | 412 206 5303 |
| Website | sharptx.com |
Stock Details
| Ticker Symbol | SHRX |
| Exchange | TSX Venture Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Dr. Scott F. Sneddon J.D., Ph.D. | Chief Executive Officer, Chief Science Officer and Director |
| Marcel P. Bruchez Ph.D. | Scientific Co-Founder and Chief Technology Officer |
| Dr. Alan S. Waggoner Ph.D. | Scientific Co-Founder and Chief Architect |
| Edward Jonasson CA CPA | Chief Financial Officer |
| Lorne Michael Sugarman | Director and Corporate Secretary |